

# Alexander M Popov

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2820929/publications.pdf>

Version: 2024-02-01

27  
papers

284  
citations

932766

10  
h-index

1058022

14  
g-index

27  
all docs

27  
docs citations

27  
times ranked

291  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with <i>KMT2A</i> gene rearrangements. <i>British Journal of Haematology</i> , 2023, 201, 510-519.	1.2	8
2	Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia. <i>Blood Advances</i> , 2023, 7, 953-962.	2.5	8
3	Strong expansion of normal CD19 <sup>negative</sup> B <sup>cell</sup> precursors after the use of blinatumomab in the first <sup>line</sup> therapy of acute lymphoblastic leukaemia in children. <i>British Journal of Haematology</i> , 2022, 196, .	1.2	6
4	Immune reconstitution following rituximab-based immunochemotherapy in pediatric patients with B-cell non-Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 2022, 63, 217-221.	0.6	3
5	Lineage switch to acute myeloid leukemia during induction chemotherapy for early T-cell precursor acute lymphoblastic leukemia with the translocation t(6;11)(q27;q23)/KMT2A-AFDN: A case report. <i>Leukemia Research</i> , 2022, 112, 106758.	0.4	5
6	Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4019.	1.8	18
7	Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)-expressing T cells. <i>Haematologica</i> , 2022, 107, 970-974.	1.7	6
8	A simple algorithm with one flow cytometric MRD measurement identifies more than 40% of children with ALL who can be cured with low-intensity therapy. The ALL-MB 2008 trial results. <i>Leukemia</i> , 2022, 36, 1382-1385.	3.3	6
9	Incidence and prognostic value of central nervous system involvement in infants with B <sup>cell</sup> precursor acute lymphoblastic leukemia treated according to the MLL <sup>Baby</sup> protocol. <i>Pediatric Blood and Cancer</i> , 2022, 69, .	0.8	3
10	B <sup>cell</sup> lineage antigens that are useful to substitute <i>CD19</i> for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after <i>CD19</i> targeting. <i>Cytometry Part B - Clinical Cytometry</i> , 2022, 102, 353-359.	0.7	11
11	Quantification of NG2 <sup>positivity</sup> for the precise prediction of KMT2A gene rearrangements in childhood acute leukemia. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 88-99.	1.5	8
12	Additional flow cytometric studies for differential diagnosis between Burkitt lymphoma/leukemia and B-cell precursor acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2021, 100, 106491.	0.4	3
13	Relative expansion of CD19 <sup>negative</sup> very <sup>early</sup> normal B <sup>cell</sup> precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR <sup>T</sup> cell therapy: implications for flow cytometric detection of minimal residual disease. <i>British Journal of Haematology</i> , 2021, 193, 602-612.	1.2	30
14	Blinatumomab following haematopoietic stem cell transplantation <sup>is</sup> a novel approach for the treatment of acute lymphoblastic leukaemia in infants. <i>British Journal of Haematology</i> , 2021, 194, 174-178.	1.2	8
15	The use of additional immunophenotypic criteria for the differential diagnosis of Burkitt lymphoma/leukemia: An exemplary case report. <i>Leukemia Research</i> , 2021, 110, 106662.	0.4	1
16	Chimerism evaluation in measurable residual disease <sup>suspected</sup> cells isolated by flow cell sorting as a reliable tool for measurable residual disease verification in acute leukemia patients after allogeneic hematopoietic stem cell transplantation. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 568-573.	0.7	12
17	Prognostic value of minimal residual disease measured by fusion <sup>gene</sup> transcript in infants with <i>KMT2A</i> <sup>rearranged</sup> acute lymphoblastic leukaemia treated according to the MLL <sup>Baby</sup> protocol. <i>British Journal of Haematology</i> , 2021, 193, 1151-1156.	1.2	8
18	Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia who have been treated with blinatumomab. <i>Haematologica</i> , 2021, 106, 2009-2012.	1.7	18

#	ARTICLE	IF	CITATIONS
19	An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report. <i>Cancers</i> , 2021, 13, 6148.	1.7	24
20	High-throughput sequencing of T cell receptor alpha chain clonal rearrangements at the DNA level in lymphoid malignancies. <i>British Journal of Haematology</i> , 2020, 188, 723-731.	1.2	13
21	Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols. <i>Leukemia</i> , 2020, 34, 3042-3046.	3.3	13
22	Heterogeneity of childhood acute leukemia with mature B-cell immunophenotype. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2803-2811.	1.2	7
23	Absolute count of leukemic blasts in cerebrospinal fluid as detected by flow cytometry is a relevant prognostic factor in children with acute lymphoblastic leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1331-1339.	1.2	24
24	Prognostic value of initial bone marrow disease detection by multiparameter flow cytometry in children with neuroblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 535-542.	1.2	15
25	Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27354.	0.8	12
26	An inter-laboratory comparison of PNH clone detection by high-sensitivity flow cytometry in a Russian cohort. <i>Hematology</i> , 2015, 20, 31-38.	0.7	12
27	Does ATRA Confirm to Play a Role in the Better Relapse Free Survival of Infants with Acute Lymphoblastic Leukemia?. <i>Blood</i> , 2011, 118, 1515-1515.	0.6	2